バイオシミラーの世界市場レポート 2025年

バイオシミラー市場規模は、今後数年で急成長が見込まれます。2029年には17.7%のCAGRで421億6,000万米ドルに成長します。予測期間の成長は、がんの有病率の増加、顆粒球コロニー刺激因子（G-CSF）による予防需要の増加、医療費の増加、新興国の高いポテンシャル、技術の進歩、生物製剤の高い普及率、人口の高齢化、医療へのアクセスの増加が成長の原動力になると考えられます。予測期間における主要動向としては、効果的かつ革新的な医薬品開発のための強固な研究開発活動の重視、M&A成長戦略の重視、戦略的パートナーシップの確立の重視、投資拡大の重視、人工知能の重視などが挙げられます。

バイオシミラー市場は、関節炎、喘息、がんなどの慢性疾患の蔓延が深刻化していることから、大きな成長が見込まれています。長時間労働、身体活動の制限、不健康なライフスタイルなどの要因が、これらの疾患の発生を増加させる要因となっており、バイオシミラーはますます好ましい治療オプションになりつつあります。バイオシミラーは、がん細胞に対する免疫系反応を刺激し、がん細胞の体外排出を助けるという重要な役割を担っています。国連の予測によると、2030年までに慢性疾患は世界の死亡原因の約70％を占め、慢性疾患の世界的負担は約60％に達すると予想されています。その結果、慢性疾患の急増がバイオシミラーの需要を押し上げ、バイオシミラー市場を促進することになります。

医療支出の増加が今後のバイオシミラー市場の成長を促進すると予測されています。医療支出とは、特定の人口や医療システムにおける医療商品やサービスに対する支出全体を指します。バイオシミラー市場は、高価な生物製剤に代わるより手頃な代替品を提供することで医療支出の削減に貢献し、患者や医療システムの治療費削減に寄与しています。例えば、2024年3月、英国の独立系慈善団体でありシンクタンクでもあるHealth Foundationは、イングランドにおける総医療費は、支出データの確認された最後の年である2022/23年に1,820億ポンド（1,967億8,000万米ドル）に達したと報告しました。計画された医療支出は、2024/25年度には1,920億GBP（2,075億9,000万米ドル）に増加すると予測されているが、インフレの結果、2023/24年度と比較して、実質的には0.6％のわずかな増加にとどまると予想されています。このように、医療支出の増加がバイオシミラー市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のバイオシミラーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のバイオシミラー市場：成長率分析
• 世界のバイオシミラー市場の実績：規模と成長、2019～2024年
• 世界のバイオシミラー市場の予測：規模と成長、2024～2029年、2034年
• 世界のバイオシミラー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバイオシミラー市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• モノクローナル抗体
• インスリン
• エリスロポエチン
• 顆粒球コロニー刺激因子
• その他のホルモン
• その他
• 世界のバイオシミラー市場：製品別、実績と予測、2019～2024年、2024～2029年、2034年
• 組み換え非グリコシル化タンパク質
• 組み換え糖化タンパク質
• 世界のバイオシミラー市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 腫瘍学
• 慢性疾患と自己免疫疾患
• 成長ホルモン欠乏症
• 感染症
• その他
• 世界のバイオシミラー市場、モノクローナル抗体のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• IgGバイオシミラー
• 非IgGバイオシミラー
• 世界のバイオシミラー市場、インスリンタイプのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 速効型インスリンバイオシミラー
• 持続性インスリンバイオシミラー
• 混合インスリンバイオシミラー
• 世界のバイオシミラー市場、エリスロポエチンのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• エポエチンアルファバイオシミラー
• ダルベポエチンアルファバイオシミラー
• 世界のバイオシミラー市場、顆粒球コロニー刺激因子（G-CSF）のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• フィルグラスチムバイオシミラー
• ペグフィルグラスチムバイオシミラー
• 世界のバイオシミラー市場、その他のホルモンのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 成長ホルモン
• ホルモン補充療法バイオシミラー
• 世界のバイオシミラー市場、その他、タイプ別サブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 酵素バイオシミラー
• ワクチン
• その他の生物製剤

第7章 地域別・国別分析

• 世界のバイオシミラー市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のバイオシミラー市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオシミラー市場：競合情勢
• バイオシミラー市場：企業プロファイル
  • Amgen
  • Novartis AG
  • Samsung Bioepis Co., Ltd.
  • Viatris
  • Celltrion, Inc.

第31章 その他の大手企業と革新的企業

• Coherus Biosciences
• Eli Lilly and Company
• Dr. Reddy's Laboratories
• Roche India Pvt Ltd
• Abbott India Limited
• bioMerieux India
• Becton Dickinson Private Limited
• Danaher Corporation
• Wuxi biologics
• shanghai Henlius bIoTech
• Innovent Biologics
• Hisun Pharma
• 3SBio
• Beijing ShuangLu Pharmaceuticals
• Qilu Pharmaceutical

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• バイオシミラー市場、2029年：新たな機会を提供する国
• バイオシミラー市場、2029年：新たな機会を提供するセグメント
• バイオシミラー市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs.

The main types of biosimilars are human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and others. Erythropoietin is a hormone produced by the kidneys to stimulate the production and maintenance of vital red blood cells. The various products include recombinant non-glycosylated proteins and recombinant glycosylated proteins that are used for the treatment of oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and others.

The biosimilars market research report is one of a series of new reports from The Business Research Company that provides biosimilars market statistics, including biosimilars industry global market size, regional shares, competitors with a biosimilars market share, detailed biosimilars market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilars industry. This biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biosimilars market size has grown rapidly in recent years. It will grow from $18.65 billion in 2024 to $21.95 billion in 2025 at a compound annual growth rate (CAGR) of 17.7%. The growth in the historic period can be attributed to an increase in cancer prevalence, strong economic growth in emerging markets, an increase in pharmaceutical R&D expenditure, increased healthcare expenditure, growing government initiatives, a strong pipeline of drugs, low cost of biosimilars and an increase in patent expiration.

The biosimilars market size is expected to see rapid growth in the next few years. It will grow to $42.16 billion in 2029 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to the increasing prevalence of cancer, increasing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), a rise in healthcare expenditure, high potential of emerging economies, technology advances, high penetration of biological drugs, aging population and an increase in healthcare access will drive the growth. Major trends in the forecast period include a focus on robust R&D activities for the development of effective and innovative drugs, on focus on M&A growth strategies, a focus on establishing strategic partnerships, a focus on increasing investments, and a focus on artificial intelligence.

The biosimilars market is anticipated to witness significant growth due to the escalating prevalence of chronic diseases such as arthritis, asthma, and cancer. Factors such as prolonged work hours, limited physical activity, and unhealthy lifestyle choices contribute to the increased occurrence of these conditions, for which biosimilars are increasingly becoming a preferred treatment option. Biosimilars play a crucial role in stimulating the immune system response against cancer cells, aiding in their elimination from the body. As per a United Nations projection, by 2030, chronic diseases are estimated to account for around 70% of global deaths, with the global burden of chronic disease expected to reach approximately 60%. Consequently, this upsurge in chronic disease prevalence is set to drive the demand for biosimilars, consequently propelling the biosimilars market.

The rise in healthcare expenditures is anticipated to drive the growth of the biosimilars market in the future. Healthcare expenditures refer to the overall spending on healthcare goods and services within a specific population or healthcare system. The biosimilars market contributes to reducing healthcare expenditures by providing more affordable alternatives to costly biologic drugs, which helps lower treatment costs for patients and healthcare systems. For example, in March 2024, the Health Foundation, a UK-based independent charity and think tank, reported that total health expenditures in England reached £182 billion ($196.78 billion) in the last confirmed year of spending data, 2022/23. Although planned health spending is projected to increase to £192 billion ($207.59 billion) in 2024/25, inflation is expected to result in only a modest real-term increase of 0.6% compared to the fiscal year 2023/24. Thus, the growing healthcare expenditures are fueling the expansion of the biosimilars market.

Key players in the biosimilars market are heavily invested in pioneering innovative products to establish a competitive edge. Notably, AMJEVITA marks a significant milestone as the inaugural U.S. biosimilar to Humira, a medication relied upon by over a million patients managing severe inflammatory conditions. In January 2023, Amgen Inc., a prominent biotechnology company, introduced AMJEVITA (adalimumab-atto) into the U.S. market. This biosimilar, available at 55% and 5% below the list price of Humira, offers patients a more cost-effective option.

Major companies within the biosimilars domain persist in crafting novel solutions. FYLNETRA represents a leap forward as a leukocyte growth factor designed to lower infection incidence, particularly febrile neutropenia, in patients with non-myeloid malignancies undergoing myelosuppressive anti-cancer treatments. In May 2023, Amneal Pharmaceuticals Inc., a distinguished pharmaceutical entity, launched the commercial debut of FYLNETRA (pegfilgrastim-pbbk), a Neulasta-referenced biosimilar delivered in a pre-filled single-dose syringe. FYLNETRA aims to address neutropenia, commonly experienced by chemotherapy patients, presenting a significant advancement in biosimilar-based treatments.

In November 2022, Biocon Biologics Ltd., an Indian biopharmaceutical company, announced the acquisition of Viatris Inc.'s biosimilars business for $3 billion. This strategic move aims to enhance Biocon Biologics' proximity to patients, customers, and payors by providing direct commercial capabilities and supporting infrastructure in advanced countries and various emerging regions. The merger combines Viatris' acquired global biosimilars business with Biocon Biologics' existing capabilities in research and development, global-scale manufacturing, and commercialization. Viatris Inc. is a US-based pharmaceutical company specializing in the development, licensing, manufacturing, marketing, and distribution of generic and branded medicines.

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy's Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMerieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The biosimilars market consists of sales of binocrit, epoetin alfa hexal, and abseamed. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others
• 2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins
• 3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications
• Subsegments:
• 1) By Monoclonal Antibodies: IgG Biosimilars; Non-IgG Biosimilars
• 2) By Insulin: Rapid-Acting Insulin Biosimilars; Long-Acting Insulin Biosimilars; Premixed Insulin Biosimilars
• 3) By Erythropoietin: Epoetin Alfa Biosimilars; Darbepoetin Alfa Biosimilars
• 4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars; Pegfilgrastim Biosimilars
• 5) By Other Hormones: Growth Hormones; Hormonal Replacement Therapy Biosimilars
• 6) By Others: Enzyme Biosimilars; Vaccines; Other Biologics
• Companies Mentioned: Amgen; Novartis AG; Samsung Bioepis Co., Ltd.; Viatris; Celltrion, Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biosimilars Market Characteristics

3. Biosimilars Market Trends And Strategies

4. Biosimilars Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Biosimilars Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biosimilars Market Growth Rate Analysis
• 5.4. Global Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biosimilars Total Addressable Market (TAM)

6. Biosimilars Market Segmentation

• 6.1. Global Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Insulin
• Erythropoietin
• Granulocyte-Colony Stimulating Factor
• Other Hormones
• Others
• 6.2. Global Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Non-glycosylated Proteins
• Recombinant Glycosylated Proteins
• 6.3. Global Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Chronic And Autoimmune Diseases
• Growth Hormone Deficiency
• Infectious Diseases
• Other Applications
• 6.4. Global Biosimilars Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IgG Biosimilars
• Non-IgG Biosimilars
• 6.5. Global Biosimilars Market, Sub-Segmentation Of Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rapid-Acting Insulin Biosimilars
• Long-Acting Insulin Biosimilars
• Premixed Insulin Biosimilars
• 6.6. Global Biosimilars Market, Sub-Segmentation Of Erythropoietin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epoetin Alfa Biosimilars
• Darbepoetin Alfa Biosimilars
• 6.7. Global Biosimilars Market, Sub-Segmentation Of Granulocyte-Colony Stimulating Factor (G-CSF), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Filgrastim Biosimilars
• Pegfilgrastim Biosimilars
• 6.8. Global Biosimilars Market, Sub-Segmentation Of Other Hormones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Growth Hormones
• Hormonal Replacement Therapy Biosimilars
• 6.9. Global Biosimilars Market, Sub-Segmentation Of Others, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Biosimilars
• Vaccines
• Other Biologics

7. Biosimilars Market Regional And Country Analysis

• 7.1. Global Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biosimilars Market

• 8.1. Asia-Pacific Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biosimilars Market

• 9.1. China Biosimilars Market Overview
• 9.2. China Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biosimilars Market

• 10.1. India Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biosimilars Market

• 11.1. Japan Biosimilars Market Overview
• 11.2. Japan Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biosimilars Market

• 12.1. Australia Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biosimilars Market

• 13.1. Indonesia Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biosimilars Market

• 14.1. South Korea Biosimilars Market Overview
• 14.2. South Korea Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biosimilars Market

• 15.1. Western Europe Biosimilars Market Overview
• 15.2. Western Europe Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biosimilars Market

• 16.1. UK Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biosimilars Market

• 17.1. Germany Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biosimilars Market

• 18.1. France Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biosimilars Market

• 19.1. Italy Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biosimilars Market

• 20.1. Spain Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biosimilars Market

• 21.1. Eastern Europe Biosimilars Market Overview
• 21.2. Eastern Europe Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biosimilars Market

• 22.1. Russia Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biosimilars Market

• 23.1. North America Biosimilars Market Overview
• 23.2. North America Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biosimilars Market

• 24.1. USA Biosimilars Market Overview
• 24.2. USA Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biosimilars Market

• 25.1. Canada Biosimilars Market Overview
• 25.2. Canada Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biosimilars Market

• 26.1. South America Biosimilars Market Overview
• 26.2. South America Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biosimilars Market

• 27.1. Brazil Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biosimilars Market

• 28.1. Middle East Biosimilars Market Overview
• 28.2. Middle East Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biosimilars Market

• 29.1. Africa Biosimilars Market Overview
• 29.2. Africa Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Biosimilars Market Competitive Landscape
• 30.2. Biosimilars Market Company Profiles
  • 30.2.1. Amgen Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Samsung Bioepis Co., Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Viatris Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Celltrion, Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Biosimilars Market Other Major And Innovative Companies

• 31.1. Coherus Biosciences
• 31.2. Eli Lilly and Company
• 31.3. Dr. Reddy's Laboratories
• 31.4. Roche India Pvt Ltd
• 31.5. Abbott India Limited
• 31.6. bioMerieux India
• 31.7. Becton Dickinson Private Limited
• 31.8. Danaher Corporation
• 31.9. Wuxi biologics
• 31.10. shanghai Henlius biotech
• 31.11. Innovent Biologics
• 31.12. Hisun Pharma
• 31.13. 3SBio
• 31.14. Beijing ShuangLu Pharmaceuticals
• 31.15. Qilu Pharmaceutical

32. Global Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biosimilars Market

34. Recent Developments In The Biosimilars Market

35. Biosimilars Market High Potential Countries, Segments and Strategies

• 35.1 Biosimilars Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biosimilars Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biosimilars Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer